Faropenem
Category
Pharmaceutical Actives & Precursors
Sub-Category
Active Pharmaceutical Ingredients (APIs)
Description : Faropenem sodium (CAS 106560-14-9) is experiencing a strategic resurgence in the global anti-infective segment as a critical oral carbapenem, bridging the therapeutic gap between traditional beta-lactams and parenteral carbapenem therapy for multidrug-resistant respiratory and urinary tract infections. Market intelligence indicates that the adoption of high-purity faropenem is being propelled by the clinical shift toward oral switch therapies in outpatient parenteral antimicrobial therapy (OPAT) models, particularly across the Asia-Pacific region where the burden of ESBL-producing pathogens remains high. The increasing focus on paediatric and geriatric-friendly formulations has also catalysed R&D investments into advanced granulations and taste-masking technologies, further solidifying its position as a preferred broad-spectrum agent in both hospital-acquired and community-acquired infection protocols. We are an established Faropenem API supplier with >= 99% purity globally for semi-finished formulators, providing comprehensive analytical (HPLC/NMR/MS) and supporting Faropenem COA/TDS/SDS region-specific regulatory support. reliable lead times, worldwide supply chain capabilities

![4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol](/_next/image?url=https%3A%2F%2Fcdn.scimplify.com%2Fproducts%2Fimages%2F682ac875326e2ad1cac5aa25%2F4-2-amino-3-5-dibromophenyl-methylamino-cyclohexan-1-ol.png&w=3840&q=75)







